And with regards to AXS-12 or reboxetine, you mentioned mechanistic overlap with Sunosi and how would we think about the two products?

Source: https://seekingalpha.com/article/4601604-axsome-therapeutics-inc-axsm-q1-2023-earnings-call-transcript?source=feed_all_articles

So far, in less than a year, Axsome has easily recouped its expenses (upfront payment) on Sunosi.

Source: https://seekingalpha.com/article/4598960-axsome-therapeutics-things-are-coming-together-nicely?source=feed_all_articles

With regard to Solriamfetol or Sunosi for the treatment of ADHD, we are preparing to initiate a Phase 3 trial in this indication in the first half of 2023.

Source: https://seekingalpha.com/article/4582506-axsome-therapeutics-inc-axsm-q4-2022-earnings-call-transcript?source=feed_all_articles